# Precision T1D Platform

> **NCT07594145** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Oregon Health and Science University** · enrollment: 57 (estimated)

## Conditions studied

- Type 1 Diabetes
- T1D Diabetic Chronic Kidney Disease
- T1D Heart Failure
- Cardio-renal Vascular Function and Failure

## Interventions

- **DRUG:** Finerenone
- **DRUG:** Sotagliflozin

## Key facts

- **NCT ID:** NCT07594145
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594145, "Precision T1D Platform". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07594145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*